FGFR2 and neoplasm: Particularly well-characterized gene fusions, such as NTRK-ETV6 in patients with juvenile secretory carcinoma of the breast (JSCV) with a rationale for tumor-agnostic treatment using an NTRK inhibitor (entrectinib), TRIM24-BRAF in VMM with a molecular rationale for MEK inhibitor (trametinib), as well as FGFR2-TACC2 with a therapeutic rationale for an FGFR inhibitor (pemigatinib), were identified in our cohort (Table 2).